Nitric oxide synthases (NOS) are important mediators of pro-growth signaling in tumor cells, as they regulate angiogenesis, immune response, and immune-mediated wound healing. Ionizing radiation (IR)
4 produce low flux (pM) NO over short periods of time. In contrast, the inducible isoform iNOS is Ca 2+independent and generates higher flux NO over a longer period of time that can range from nM-μM in concentration, depending upon the stimulant (11) . Nitric oxide synthase has been studied extensively in carcinogenesis. While elevated NOS3 expression has a role in tumor angiogenesis, increased NOS2 expression predicts poor therapeutic response, tumor progression, and decreased patient survival (9, (12) (13) (14) (15) . To date, our molecular signatures suggest that NO-mediated pro-survival, cell migration, angiogenesis, and stem cell marker (i.e. ERK, Akt, IL-8, IL-6, S100A8, CD44) signaling in tumors and tumor cells occurs at >400 nM steady state NO (6, 9) . Together, these observations suggest that the NOS enzymes are exploitable therapeutic targets.
Nitric oxide produced by the constitutive eNOS isoform controls blood flow and is a key mediator of the pro-angiogenic effects of vascular endothelial growth factor (VEGF) (16) . A clinical study demonstrated reduced tumor blood volume within one hour of administration of the competitive NOS inhibitor nitro-L-arginine (L-NNA), which lasted for twenty-four hours in all patients studied (17) .
Side effects of NOS inhibition included bradycardia and hypertension, which were not study limiting and suggest that NOS inhibition may be a beneficial therapeutic option for combined modalities (17) .
Advances in radiotherapy have included the co-administration of anti-angiogenic (AA) drugs, which radiosensitize endothelial cells (18) . Ionizing radiation also activates constitutive NOS, as well as ERK1/2 kinase pro-survival signaling, both of which were blocked by L-NNA (19) . In addition, the administration of L-NNA 24 hr prior to 10 Gy irradiation of tumor-bearing mice demonstrated reduced tumor blood flow and increased tumor cell apoptosis when compared to mice receiving radiation or L-NNA alone, further supporting NOS inhibition as a target to improve radiation therapeutic response (20) .
In addition to targeting tumor vasculature, IR modulates host immunity and mimics vaccine Research.
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Author Manuscript Published OnlineFirst on ; DOI: 10.1158/0008-5472.CAN-14-3011 5 response by enhancing the release of damage associated molecular patterns (DAMPs) from dying cells, which then activate cytotoxic lymphocytes (CTLs) through toll-like receptor activation (21). Ionizing radiation facilitates antigen-presenting cell and T cell penetration into the tumor (22) , and also impacts host immunity through modulation of both pro-and anti-tumor responses depending upon the Th1 (cytotoxic) vs Th2 (immunosuppressive) cytokine milieu and associated immune cell mediators (21).
Macrophages exposed to Th1 cytokines exhibit increased levels of pro-inflammatory cytokine production, antigen presentation, and cytotoxic activity. In contrast, macrophages exposed to Th2 cytokines exhibit an immunosuppressive phenotype associated with blocked CTL activity, increased angiogenesis, tissue restoration and wound healing response (23) . T-regulatory cells (Tregs) are pivotal mediators of immune suppression and the development of immunologic tolerance through their ability to limit antitumor immune responses (24) . Tregs mediate tumor immune tolerance in part through the secretion of IL-10, TGF-β, or IL-35 immunosuppressive molecules (24) . Indeed, IL-10 and TGF-β derived from Tregs promote tumor progression through antitumor immune suppression (25) . Nitric oxide also mediates both cGMP-dependent and -independent Th1-Th2 immune transition and may be important in the tumor response to radiation-induced injury (26, 27) . To explore this hypothesis, we examined cytokine expression profiles and T cell activation during radiation-induced tumor growth delay in a syngeneic model treated post-IR with the NOS inhibitor N G -nitro-L-arginine methyl ester (L-NAME).
Materials and Methods
Cell Culture. Jurkat cells (Jurkat clone E6-1) were obtained from the ATCC and maintained in 5% Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.
Author Manuscript Published OnlineFirst on May 19, 2015; DOI: 10.1158/0008-5472.CAN-14-3011 6 (0, 500 or 1000 μM), or the guanylyl cyclase inhibitor ODQ (1 μM) or thrombospondin-1 (TSP-1: 1 μg/ml). The NONOate donors including DETA/NO are stable when maintained in basic conditions (10 mM NaOH) but release NO at defined rates at physiologic pH (28); 10 mM NaOH served as vehicle control in experiments utilizing the NO donor DETA/NO. The ANA-1 macrophage cell line used in this study was established by immortalization of bone marrow macrophages from C57BL/6 mice with J2 recombinant retrovirus-expressing v-myc/v-raf oncogenes (29) . ANA-1 cells were grown in Dulbecco's modified eagle's medium (DMEM) supplemented with 10% FBS and 1% penicillin-streptomycin, plated at a density of 5x10 5 per well in a 12 well plate and grown overnight.
Suppression of IL-10.
Silencing of IL-10 protein translation was accomplished by using an antisense 25-mer oligo (Gene Tools, Philomath, OR) designed specifically to block the AUG translational start site of mouse IL-10 (GenBank accession no. NM_010548: oligo sequence, 5_-AGCTCTCTTTTCTGCAAGGCTGCTT). This oligo complements the sequence from -31 to -6 relative to the initiation codon. Suppression of secreted IL-10 protein levels were verified in LPSstimulated Raw 267.4 (30) cells pre-treated with control or IL-10 morpholino. Cell culture media was collected at 24 and 48 hr and IL-10 protein levels were measured by ELISA assay (R&D Systems, Minneapolis MN) according to the manufacturers recommendations. Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.
In Vivo

7
VII/SF tumor cells (SCC) were derived from spontaneous abdominal wall squamous cell cancer (obtained from Dr. T. Phillips, UCSF, San Francisco, CA) and propagated in C3H/Hen mice (31) .
For growth delay studies, 2x10 5 and 98.9%, respectively, when compared to the in-house control. Tumor volume was measured by caliper and calculated as mm 3 = [width 2 x length]/2 where width was the smaller dimension. Tumor irradiation was accomplished by securing each animal in a specially designed Lucite jig fitted with lead shielding that protected the body from radiation while allowing exposure of the tumor-bearing leg. A Therapax DXT300 X-ray irradiator (Pantak, Inc., East Haven, CT) using 2.0 mm A1 filtration (300 KVp) at a dose rate of 2.53 Gy/min was used as the X-ray source. Irradiated tumors received one 10 Gy dose. Designated groups of animals were treated with NOS inhibitor L-NAME or IL-10 suppressing agents. NOS inhibition was achieved by administering L-NAME post-IR in the drinking water at a concentration of 0.5g/L for the duration of the experiment (20) . IL-10 protein levels were suppressed using an IL-10 morpholino; mice were injected with a 750 μl volume of 10 μM IL-10 morpholino (Gene Tools, Philomath, OR) or a 4 base-mismatched control morpholino in saline 48 hr prior to irradiation. After irradiation, the mice were returned to their cages, and tumors were measured three times each week thereafter to assess tumor growth. Animals were euthanized when tumor growth approached the maximum allowable limit. Jurkat and CD47-deficient JinB8 Jurkat cells (~1x10 6 ) (33) were plated on 12-well plates (Corning) using RPM1 medium + 2% FBS at 37 °C in 5% CO 2 and treated with 1 μg/ml TSP1 for 6 h.
Untreated cells were used as controls. Total RNA was extracted using TriPure Isolation Reagent Statistics All results are expressed as the mean ± SEM. The differences in means of groups were determined by the Student's t-test with the minimum level of significance set at P < 0.05.
Results
NOS Inhibition Enhances Radiation-Induced Tumor Growth Delay in Syngeneic Mice
Tumor growth delay is described by the substance enhancement ratio (SER), which is the ratio of time required for treated vs. control tumors to reach a defined size (1000 mm 3 ). The effect of NOS inhibition by L-NAME, a NOS inhibitor that is more selective for the constitutive isoforms (35) (eNOS and nNOS), on radiation-induced tumor growth delay was examined in a syngeneic murine model of SCC tumor-bearing C3H mice. L-NAME was administered in the animals' drinking water (0.5 g/L) following tumor irradiation (post-IR, 10 Gy). Because NO regulates vascular tonicity, we chose post-IR administration of L-NAME to minimize vascular constriction and maintain tumor pO 2 prior to and Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.
Author Manuscript Published OnlineFirst on May 19, 2015; DOI: 10.1158/0008-5472.CAN- during tumor irradiation while targeting vascular constriction post-IR. Figure 1A demonstrates enhanced radiation-induced tumor growth delay in mice that received post-IR L-NAME (SER ~ 3.3) when compared to tumors treated with 10 Gy IR alone (SER ~ 1.8). The iNOS-specific inhibitor aminoguanidine was also tested, and yielded an SER of 2.1. Interestingly, L-NAME-mediated NOS inhibition had no effect on the radiation-induced tumor growth delay of HT29 human adenocarcinoma cells or SCC xenografts in immunosuppressed nude mice lacking T cells ( Figure 1B , 1C, respectively).
These results indicate a requirement of T cells for L-NAME potentiation of radiation-induced tumor growth delay.
Effect of L-NAME on Radiation-Induced Cytokine Expression in Syngeneic Mice
T cells are lymphocytes that direct cell-mediated immunity and are distinguished from other lymphocytes by the presence of cell surface T-cell receptors. There are several subsets of T cells, each with a distinct function; proliferating helper T cells differentiate into two major types of effector T cells known as Th1 and Th2 cells, which secrete specific cytokines that mediate different immune responses.
Th1 cells are pro-inflammatory, mediate host immunity to foreign pathogens, and are induced by IL-2, IL-12, and their effector cytokine IFN-γ (36) . In contrast, Th2 cells are immunosuppressive, secrete IL-4, IL-5, IL-10 as well as TGF-β, and mediate wound resolution following pro-inflammatory assault (37) .
To explore a potential role for NOS-derived NO during radiation-induced T-cell response, QPlex was used to examine alterations in tumor cytokine expression. Supplemental Table I Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.
Author Manuscript Published OnlineFirst on May 19, 2015; DOI: 10.1158/0008-5472.CAN- followed by increased IL-5, IL-3, and IL-4 tumor expression (Day 2-4). In contrast, tumors from animals that received post-IR L-NAME exhibited a Th1 profile as defined by elevated IL-2 (6 Hr, Day 1), IL-12, and IFN-γ (Day 3, 4, 7) tumor expression. The most profound observation pertained to the dramatic early induction of IL-10 24 hrs post-IR, which was abated by L-NAME (Figure 2A) . These results suggest the rapid induction of an IL-10-mediated immunosuppressive phenotype in response to tumor irradiation, which was abolished by post-IR NOS inhibition. We also examined tumor NOS isoform protein expression 24 hr Post-IR. When compared to control, Figure 2B shows increased iNOS protein expression in the 10 Gy and 10 Gy + L-NAME tumors. This is an interesting observation considering that constitutive NOS inhibition by L-NAME was more effective in extending the radiationinduced tumor growth delay. This may be explained by the findings of Connelly et al. who demonstrated that eNOS is required for the full activation of iNOS (38) .
Nitric Oxide-Induced IL-10 Expression in Jurkat T Cells and ANA-1 Macrophages
IL-10 is generally produced by differentiated monocytes and lymphocytes (i.e. macrophages and T cells, respectively). To further examine the involvement of NO during radiation induced IL-10 expression, we used Jurkat cells, which are T lymphocytes that express IL-10 and are commonly employed to study T cell signaling. Cytokine expression profiles were examined in cells exposed to the slow releasing NO donor DETA/NO, which mimics NO flux under inflammatory conditions. Figure 3 demonstrates NO concentration-dependent induction of IL-10 mRNA (A) and protein (B) in Jurkat cells, which peaked at 300 µM DETA/NO. Next, Jurkat cells were exposed to 1 Gy irradiation, then treated with or without L-NAME and incubated overnight to mimic the tumor xenograft irradiation protocol. Figure 3C shows a greater than 4-fold increase in Jurkat IL-10 expression 24 hr after 1 Gy irradiation, which was abated by L-NAME and is similar to the L-NAME effect on radiation-induced tumor IL-10 expression shown in Figure 2 . Interestingly, the L-NAME suppressed IL-10 levels re-accumulated to Figure 3C ). To date, our breast cancer biomarker signatures suggest that NO-mediated pro-survival, cell migration, angiogenesis, and stem cell marker (i.e. ERK, Akt, IL-8, IL-6, S100A8, CD44) signaling in tumors and tumor cells occurs at > 400 nM steady state NO (6, 7, 9, 12, 39) . When considering this molecular signature, the results shown in Figure 3A -C are consistent with our earlier reports and suggest that ~400nM steady state NO modulates radiation-induced IL-10 expression in Jurkat cells. Also, the NO flux-dependent regulatory trend of IL-10 shown in Figure 3C resembles a bell shaped curve, which is consistent with low flux NO regulation of wound response vs. high flux NO-mediated toxicity (11, (40) (41) (42) .
L-NAME is more selective for the constitutive NOS isoforms, which implicates possible eNOS/cGMP-dependent signaling (35, 43) . To explore the potential of cGMP-dependent signaling during radiation-induced IL-10 expression, Jurkat cells were exposed to 1 Gy IR +/-the guanylyl cyclase inhibitor ODQ, which completely abolished IL-10 expression induced by 1 Gy IR ( Figure 3D ).
Thrombospondin-1 (TSP-1) inhibits NO signaling through its receptor CD47 by inhibiting eNOS activation and abating NO-dependent cGMP synthesis and cGMP-dependent protein kinase signaling in vascular cells and Jurkat T cells (41, 42) . Exogenous TSP-1 also blocked radiation-induced Jurkat IL-10 expression, suggesting eNOS/cGMP-dependence for this process ( Figure 3D ). Inhibition of IL-10 expression by TSP-1 is CD47-dependent because inhibition of basal IL-10 mRNA expression was lost in the CD47-deficient Jurkat mutant JinB8 ( Figure 3E ). The 2-fold stimulation of IL-10 mRNA by TSP-1 in the CD47 mutant is consistent with reported positive effects of TSP-1 on IL-10 expression mediated by the TSP-1 receptor CD36 (44) . Radiation also induced IL-10 in murine ANA-1 macrophages, which was abated by L-NAME, ODQ and TSP-1, indicating that cGMP-dependent regulation of IL-10 is not Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.
Author Manuscript Published OnlineFirst on May 19, 2015; DOI: 10.1158/0008-5472.CAN- restricted to T cells ( Figure 3F ). Collectively, these results indicate that radiation-induced IL-10 expression in T cells is tightly controlled by low constitutive NOS-derived NO flux.
IL-10 Suppression Enhances Radiation-induced Tumor Growth Delay
Post-IR NOS inhibition by L-NAME enhanced radiation-induced tumor growth delay and abated radiation-induced IL-10 expression ( Figure 1A and Figure 2 , respectively). To examine a role of IL-10 in the recovery from post-IR tumor growth delay, IL-10 protein translation was suppressed by treatment with an IL-10 morpholino (45, 46) . Confirmation of the morpholino efficacy for IL-10 protein suppression was verified using LPS-stimulated Raw 267.4 cells because LPS is a strong inducer of IL-10 in these cells (30) as shown in Figure 4A . Next, tumor-bearing animals were treated with IL-10 or control morpholino 48 hr prior to tumor irradiation. IL-10 morpholino treatment enhanced the radiationinduced tumor growth delay (SER ~2.7) as shown in Figure 4B in a manner similar to that observed by L-NAME ( Figure 1A ) but had no effect on tumor growth in the absence of radiation. These results suggest that radiation-induced tumor growth delay can be improved by inhibiting IL-10-mediated immunosuppressive signaling in the C3H/SCC syngeneic model.
L-NAME Increases Tumor-associated CD8 + Cytolytic T Cells Post-IR
Cytotoxic T lymphocytes are a subgroup of T cells that when activated kill invading pathogens and tumor cells. These cells are commonly referred to as CD8 + T cells because they express cell surface CD8 glycoprotein. Importantly, immunosuppressive molecules including IL-10 can inactivate CD8 + T cells. To identify the presence of CD8 + T cells, markers of tumor lymphocyte infiltration were examined in control and 10 Gy + L-NAME tumors, as well as spleen from tumor-bearing mice. Figure 5A shows increased tumor-associated CD8 + T cells in irradiated tumors treated with L-NAME but not spleen taken from the same animals ( Figure 5B ). CD69 is a marker of T cell activation. Figure 5C Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.
Author Manuscript Published OnlineFirst on May 19, 2015; DOI: 10.1158/0008-5472.CAN-14-3011 treated with L-NAME but not in spleen taken from the same animals ( Figure 5D ). Importantly, these results implicate a localized tumor response culminating in the elevation of activated cytotoxic T cells in post-IR NOS inhibited tumors. Neutrophils, dendritic cells, and immature myeloid cells from post-IR treated L-NAME tumors were elevated on day 3, when compared to irradiated tumors ( Figure 5 E-G) . In contrast, Tregs and natural killer cells did not change (Figure 5 H,I) . Collectively, these results demonstrate that altered NO flux via L-NAME-mediated NOS inhibition can improve the efficacy of therapeutic radiation by immune polarization favoring a pro-inflammatory phenotype within the tumor microenvironment in a SCC/C3H syngeneic model. L-NAME is more selective for inhibiting the constitutive NOS isoforms (eNOS and nNOS) and our cell culture results implicate eNOS/cGMP-dependent signaling (Figure 3 ) in the immune polarization shown in Figure 5 . To further explore a role of eNOS in the potentiation of radiation therapeutic efficacy, we examined the radiation-induced tumor growth delay of murine B16 melanoma xenografts in wild type (WT) and eNOS knockout (eNOS -/-) mice on the C57BL/6 background ( Figure   6A ). When compared to control, the irradiated tumor in WT mice yielded an SER of ~ 2 ( Figure 6A ), which is consistent with the SCC/C3H syngeneic model shown in Figure 1A . Remarkably, the irradiated tumor in eNOS -/animals exhibited an SER of ~ 5.5 when compared to the WT irradiated tumor ( Figure   6A ). Interestingly, IL-10 protein was not detected in B16 xenografts grown in WT C57BL/6 or eNOS -/on the same background under these conditions, however the cytokine protein expression profile of irradiated tumors in eNOS -/mice exhibited significantly elevated Th1 cytokines including IL-2, TNF-α, and IFN-γ as shown in Figure 6 panels B-D. Importantly, radiation has been shown to induce eNOS expression, which promotes tumor recovery from radiation injury (47) . Together, these results suggest that eNOS has a vital role in acute tumor radiation response and that improved pharmacology of NOS inhibitors in combination with radiation may be therapeutically beneficial. 
Discussion
The role of NO flux within the tumor microenvironment as it relates to therapeutic efficacy is complex. Studies have shown that steady state NO modulation within the tumor microenvironment leads to improved radiation therapeutic efficacy (20, 47, 48) . Nitric oxide mediates numerous effects at the cellular and physiological levels. Similar to molecular O 2 , the outer π orbital of NO has an unpaired electron, which imparts a high affinity for other radicals including radiation-induced carbon radicals on DNA, which leads to fixed DNA damage and enhanced NO-mediated radiosensitivity (49) . In support of this early observation, a recent study demonstrated that the presence of low steady state NO dramatically enhanced radiosensitization as well as increased the time of DNA repair, when compared to anoxic and aerated control tumors (50) . Similarly, site-specific iNOS transgene expression driven by the radiationinducible pE9 promoter demonstrated enhanced tumor radiation response under hypoxic conditions (51) .
In addition to these direct effects of NO-mediated radiosensitization, altered NO gradients prior to tumor irradiation have been shown to normalize tumor vasculature, which increased tumor oxygen tension and tumor response to radiation (52) . In contrast, administration of the NOS inhibitor L-NAME before and after radiation minimized the cytotoxic effect of NO under conditions of hypoxia (48) . In this context, NO improved radiation therapeutic efficacy by enhanced tumor perfusion and oxygen effect (53) . Thus, NO modulation prior to and at the time of radiation is therapeutically beneficial. Together, these studies demonstrate the contextual dependence of timing and distinct mechanisms directed by NO flux for improved tumor response to radiation therapy. Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.
Author Manuscript Published OnlineFirst on May 19, 2015; DOI: 10.1158/0008-5472.CAN- vivo models have shown delayed wound closure in iNOS knockout mice (55) . Toward this end, ionizing radiation-induced angiogenesis (56) through NO signaling (47) , which promoted tumor recovery following radiation injury. These observations suggest that post-irradiation inhibition of angiogenesis may be beneficial. Thus we hypothesized that improved radiation therapeutic efficacy and extended tumor growth delay may be achievable by targeting NO flux through NOS inhibition following tumor irradiation.
Interestingly, post-IR administration of the constitutive NOS inhibitor L-NAME extended radiation-induced tumor growth delay and was more effective than the selective iNOS inhibitor aminoguanidine ( Figure 1A) . Moreover, L-NAME extended the radiation-induced tumor growth delay only in syngeneic mice but not nude mice. This observation implicates the involvement of innate immunity and cytotoxic T cells in enhanced radiosensitivity, which is regulated by NO flux, and further supported by the cytokine expression profile of post-IR NOS-inhibited tumors that expressed high levels of cytotoxic Th1 cytokines including IL-2, IFN-γ, and IL-12p40 as summarized in Figure 7 . In contrast, tumors receiving radiation alone exhibited immunosuppressive Th2 signaling, as indicated by increased IL-10, IL-5, and IL-4 cytokine expression (Supplemental Table I and II) . Moreover, tumor cytokine expression analysis revealed enhanced IL-10 protein levels 24 hr following tumor irradiation in SCCtumor bearing C3H mice, which was abolished by L-NAME ( Figure 2 ) and confirmed in irradiated Jurkat T lymphocytes, ANA-1 macrophages (Figure 3 ). Importantly, in vivo IL-10 protein suppression extended radiation-induced tumor growth delay in C3H mice in a manner similar to that of L-NAME.
These findings implicate a novel role for NO as a stimulator of IL-10-mediated tumor immunosuppressive signaling, which accelerates tumor recovery and regrowth in response to radiation injury in the C3H model. Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.
Author Manuscript Published OnlineFirst on May 19, 2015; DOI: 10.1158/0008-5472.CAN- Cytokine expression analysis of ANA-1 macrophages, and Jurkat T cells demonstrated increased IL-10 expression 24 hr after 1 Gy irradiation, which was abated by L-NAME, suggesting that radiationinduced IL-10 could come from these cell types. Although we used a variety of sensitive detection methods including flow cytometry analysis of IL-10 associated with markers of specific immune cell populations, as well as flow cytometry analysis of GFP-IL-10-tagged mice, we were unable to confirm the specific cellular source of IL-10 in our experiments. In addition, no significant changes in Treg cell populations were observed that might account for the cellular source of increased IL-10 levels following irradiation. Ongoing studies are aimed at identifying the relative contributions of leukocyte subsets to IL-10 following tumor irradiation. Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.
Author Manuscript Published OnlineFirst on May 19, 2015; DOI: 10.1158/0008-5472.CAN- The post-IR NOS-inhibited tumor exhibited enhanced expression of IL-2, IFN-γ, and IL-12p40 Th1 mediators ( Supplemental Table I ). IL-2 is a pleiotropic cytokine that has pivotal roles during immune regulation in response to foreign pathogens (59) . IL-2 is produced primarily by CD4 + T cells and promotes the differentiation, expansion, and cytolytic activation of cytotoxic T cells. Importantly, IL-2 effects are receptor-mediated; IL-2 interaction with IL-12Rβ2 leads to up-regulation of IFN-γ and IL-12 during Th1 cell differentiation (59) . Interestingly, a cGMP-dependent role of low flux NO in the selective upregulation of IL-12Rβ2 has been reported (26) . IL-12 is also important for sustaining memory/effector T cells, which promote long-term protection against pathogens and tumors. IL-2 also interacts with IL-2Rα to promote CD8 + T cell differentiation and activation (59) . Importantly, these cytokine activation profiles are consistent with the time course analysis showing elevated IL-2, IFN-γ, and IL-12p40 in the post-IR NOS-inhibited tumors summarized in Supplemental Table I , as well as CD8 + T cell regulation shown in Figure 5 . In contrast, tumors receiving irradiation alone demonstrated increased IL-10 followed by elevated Th2 mediators IL-5, IL-3, and IL-4. Interestingly, IL-2 was also elevated in these irradiated tumors and may have played a role in the upregulation of IL-4 and IL-5 Th2 cell differentiation, which is IL-4Rα dependent (59) . The pro-inflammatory cytokine IL-1α was also observed in the irradiated tumor. Despite its pro-inflammatory status, IL-1α released by solid tumors acts as a chemoattractant to facilitate malignancy-associated inflammatory responses (60) .
Collectively, the results herein suggest a novel mechanism of low flux NO during Th1-Th2 transition, tumor immunosuppressive signaling, and accelerated wound recovery in the tumor response to ionizing irradiation. Importantly, CD8 + T cell regulation and IFN-γ expression seem to be determined by NO flux-dependent IL-10 verses IL-2 signaling cascades, which can be modulated by pharmacological NOS inhibition and may provide a novel immunotherapeutic approach for improved radiation therapeutic efficacy. Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.
Author Manuscript Published OnlineFirst on May 19, 2015; DOI: 10.1158/0008-5472.CAN-14-3011 Post-IR aminoguanidine, a selective iNOS inhibitor, was less effective than L-NAME at extending radiation-induced tumor growth delay (A). Human HT29 colon carcinoma (B) and SCC (C) xenografts grown in female athymic nude mice show no effect of post-IR L-NAME on radiationinduced tumor growth delay. Mice were injected with 2x10 5 SCC (A and C) or 1x10 6 HT29 (B) tumor cells in the right hind leg and grown for one week to allow formation of palpable tumors of uniform size (~200 mm 3 ). On day seven animals received tumor irradiation +/-post-IR L-NAME (or aminoguanidine) in the animals drinking water (0.5g/L). Data are presented as mean + SEM, n > 5 animals per group. 
Figure Legends
